Senior insider sale
Chief R&D Officer at NEKTAR THERAPEUTICS — senior position signals high conviction
$341.9K
5.74K shares
What this filing means
ZALEVSKY JONATHAN plans to sell 5.74K shares of NEKTAR THERAPEUTICS valued at approximately $341.9K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/15/2026ACC: 0001950047-26-006135
Officer· Chief R&D Officer
Since Oct 2019
5.74K
Shares to sell
$341.9K
Approx. market value
5.54K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months1
Restricted Stock Units
N/A
5/15/2021
5.54KTotal acquired5.54K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
5/15/2021 | Restricted Stock Units N/A | 5.54K | — |
| Total | 5.54K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
199.00
Market value
$13.0K
5/19/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
5.54K
Market value
$328.8K
6/15/2026
Total
Units
5.74K
Value
$341.9K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
5/19/2026 | 199.00 | $13.0K | — | Completed |
| Planned — Approximate Date | ||||
6/15/2026 | 5.54K | $328.8K | NASDAQ | Planned |
| Total | 5.74K | $341.9K | ||